TY - JOUR AU - Siegel, R. AU - Ma, J. AU - Zou, Z. AU - Jemal, A. PY - 2014 DA - 2014// TI - Cancer statistics, 2014 JO - CA Cancer J Clin VL - 64 UR - https://doi.org/10.3322/caac.21208 DO - 10.3322/caac.21208 ID - Siegel2014 ER - TY - JOUR AU - Corfield, J. AU - Perera, M. AU - Bolton, D. AU - Lawrentschuk, N. PY - 2018 DA - 2018// TI - 68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review JO - World J Urol VL - 36 UR - https://doi.org/10.1007/s00345-018-2182-1 DO - 10.1007/s00345-018-2182-1 ID - Corfield2018 ER - TY - JOUR AU - Han, S. AU - Woo, S. AU - Kim, Y. J. AU - Suh, C. H. PY - 2018 DA - 2018// TI - Impact of 68 Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis JO - Eur Urol VL - 74 UR - https://doi.org/10.1016/j.eururo.2018.03.030 DO - 10.1016/j.eururo.2018.03.030 ID - Han2018 ER - TY - STD TI - von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G. 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography for prostate cancer: a systematic review and meta-analysis. Eur Urol Focus. 2016. ID - ref4 ER - TY - JOUR AU - Hofman, M. S. AU - Lawrentschuk, N. AU - Francis, R. J. PY - 2020 DA - 2020// TI - Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study JO - Lancet (London, England) VL - 395 UR - https://doi.org/10.1016/S0140-6736(20)30314-7 DO - 10.1016/S0140-6736(20)30314-7 ID - Hofman2020 ER - TY - JOUR AU - Fendler, W. P. AU - Eiber, M. AU - Beheshti, M. PY - 2017 DA - 2017// TI - 68Ga-PSMA PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0 JO - Eur J Nucl Med Mol Imaging VL - 44 UR - https://doi.org/10.1007/s00259-017-3670-z DO - 10.1007/s00259-017-3670-z ID - Fendler2017 ER - TY - JOUR AU - Parker, C. C. AU - James, N. D. AU - Brawley, C. D. PY - 2018 DA - 2018// TI - Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial JO - Lancet VL - 392 UR - https://doi.org/10.1016/S0140-6736(18)32486-3 DO - 10.1016/S0140-6736(18)32486-3 ID - Parker2018 ER - TY - JOUR AU - Burdett, S. AU - Boevé, L. M. AU - Ingleby, F. C. PY - 2019 DA - 2019// TI - Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis JO - Eur Urol VL - 76 UR - https://doi.org/10.1016/j.eururo.2019.02.003 DO - 10.1016/j.eururo.2019.02.003 ID - Burdett2019 ER - TY - JOUR AU - Rosenthal, S. A. AU - Hu, C. AU - Sartor, O. PY - 2019 DA - 2019// TI - Effect of chemotherapy with docetaxel with androgen suppression and radiotherapy for localized high-risk prostate cancer: the randomized phase III NRG oncology RTOG 0521 trial JO - J Clin Oncol VL - 37 UR - https://doi.org/10.1200/JCO.18.02158 DO - 10.1200/JCO.18.02158 ID - Rosenthal2019 ER - TY - JOUR AU - Fizazi, K. AU - Faivre, L. AU - Lesaunier, F. PY - 2015 DA - 2015// TI - Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)00011-X DO - 10.1016/S1470-2045(15)00011-X ID - Fizazi2015 ER - TY - JOUR AU - James, N. D. AU - Bono, J. S. AU - Spears, M. R. PY - 2017 DA - 2017// TI - Abiraterone for prostate cancer not previously treated with hormone therapy JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1702900 DO - 10.1056/NEJMoa1702900 ID - James2017 ER - TY - JOUR AU - Davis, I. D. AU - Martin, A. J. AU - Stockler, M. R. PY - 2019 DA - 2019// TI - Enzalutamide with standard first-line therapy in metastatic prostate cancer JO - N Engl J Med VL - 381 UR - https://doi.org/10.1056/NEJMoa1903835 DO - 10.1056/NEJMoa1903835 ID - Davis2019 ER - TY - JOUR AU - Chi, K. N. AU - Agarwal, N. AU - Bjartell, A. PY - 2019 DA - 2019// TI - Apalutamide for metastatic, castration-sensitive prostate cancer JO - N Engl J Med VL - 381 UR - https://doi.org/10.1056/NEJMoa1903307 DO - 10.1056/NEJMoa1903307 ID - Chi2019 ER - TY - JOUR AU - Vaz, S. AU - Hadaschik, B. AU - Gabriel, M. AU - Herrmann, K. AU - Eiber, M. AU - Costa, D. PY - 2020 DA - 2020// TI - Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients JO - Eur J Nucl Med Mol Imaging VL - 47 UR - https://doi.org/10.1007/s00259-019-04529-8 DO - 10.1007/s00259-019-04529-8 ID - Vaz2020 ER - TY - JOUR AU - Watt, F. AU - Martorana, A. AU - Brookes, D. E. PY - 2001 DA - 2001// TI - A tissue-specific enhancer of the prostate-specific membrane antigen gene, FOLH1 JO - Genomics VL - 73 UR - https://doi.org/10.1006/geno.2000.6446 DO - 10.1006/geno.2000.6446 ID - Watt2001 ER - TY - JOUR AU - Murga, J. D. AU - Moorji, S. M. AU - Han, A. Q. AU - Magargal, W. W. AU - DiPippo, V. A. AU - Olson, W. C. PY - 2015 DA - 2015// TI - Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer JO - Prostate VL - 75 UR - https://doi.org/10.1002/pros.22910 DO - 10.1002/pros.22910 ID - Murga2015 ER - TY - JOUR AU - Evans, M. J. AU - Smith-Jones, P. M. AU - Wongvipat, J. PY - 2011 DA - 2011// TI - Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen JO - Proc Natl Acad Sci VL - 108 UR - https://doi.org/10.1073/pnas.1106383108 DO - 10.1073/pnas.1106383108 ID - Evans2011 ER - TY - JOUR AU - Schmuck, S. AU - Klot, C. A. AU - Henkenberens, C. PY - 2017 DA - 2017// TI - Initial Experience with Volumetric 68Ga-PSMA I&T PET/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with prostate cancer JO - J Nucl Med VL - 58 UR - https://doi.org/10.2967/jnumed.117.193581 DO - 10.2967/jnumed.117.193581 ID - Schmuck2017 ER - TY - JOUR AU - Eiber, M. AU - Herrmann, K. AU - Calais, J. PY - 2018 DA - 2018// TI - Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT JO - J Nucl Med VL - 59 UR - https://doi.org/10.2967/jnumed.117.198119 DO - 10.2967/jnumed.117.198119 ID - Eiber2018 ER - TY - JOUR AU - Eder, M. AU - Neels, O. AU - Müller, M. PY - 2014 DA - 2014// TI - Novel preclinical and radiopharmaceutical aspects of [68Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer JO - Pharmaceuticals VL - 7 UR - https://doi.org/10.3390/ph7070779 DO - 10.3390/ph7070779 ID - Eder2014 ER - TY - JOUR AU - Fanti, S. AU - Minozzi, S. AU - Morigi, J. J. PY - 2017 DA - 2017// TI - Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions JO - Eur J Nucl Med Mol Imaging VL - 44 UR - https://doi.org/10.1007/s00259-017-3725-1 DO - 10.1007/s00259-017-3725-1 ID - Fanti2017 ER - TY - JOUR AU - Larson, S. M. AU - Erdi, Y. AU - Akhurst, T. PY - 1999 DA - 1999// TI - Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis JO - Clin Positron Imaging VL - 2 UR - https://doi.org/10.1016/S1095-0397(99)00016-3 DO - 10.1016/S1095-0397(99)00016-3 ID - Larson1999 ER - TY - JOUR AU - Gravis, G. AU - Boher, J. M. AU - Joly, F. PY - 2016 DA - 2016// TI - Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial JO - Eur Urol VL - 70 UR - https://doi.org/10.1016/j.eururo.2015.11.005 DO - 10.1016/j.eururo.2015.11.005 ID - Gravis2016 ER - TY - JOUR AU - Hori, S. AU - Jabbar, T. AU - Kachroo, N. AU - Vasconcelos, J. C. AU - Robson, C. N. AU - Gnanapragasam, V. J. PY - 2011 DA - 2011// TI - Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer JO - J Cancer Res Clin Oncol VL - 137 UR - https://doi.org/10.1007/s00432-010-0877-9 DO - 10.1007/s00432-010-0877-9 ID - Hori2011 ER - TY - JOUR AU - Aggarwal, R. AU - Wei, X. AU - Kim, W. PY - 2018 DA - 2018// TI - Heterogeneous flare in prostate-specific membrane antigen positron emission tomography tracer uptake with initiation of androgen pathway blockade in metastatic prostate cancer JO - Eur Urol Oncol VL - 1 UR - https://doi.org/10.1016/j.euo.2018.03.010 DO - 10.1016/j.euo.2018.03.010 ID - Aggarwal2018 ER - TY - JOUR AU - Vallabhajosula, S. AU - Jhanwar, Y. AU - Tagawa, S. PY - 2016 DA - 2016// TI - 99mTc-MIP-1404 planar and SPECT scan: Imaging biomarker of androgen receptor (AR) signaling and prostate specific membrane antigen (PSMA) expression JO - J Nucl Med VL - 57 ID - Vallabhajosula2016 ER - TY - JOUR AU - Zacho, H. D. AU - Petersen, L. J. PY - 2018 DA - 2018// TI - Bone flare to androgen deprivation therapy in metastatic, hormone-sensitive prostate cancer on 68Ga-prostate-specific membrane antigen PET/CT JO - Clin Nucl Med VL - 43 UR - https://doi.org/10.1097/RLU.0000000000002273 DO - 10.1097/RLU.0000000000002273 ID - Zacho2018 ER - TY - JOUR AU - Liu, T. AU - Wu, L. Y. AU - Fulton, M. D. AU - Johnson, J. M. AU - Berkman, C. E. PY - 2012 DA - 2012// TI - Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells JO - Int J Oncol VL - 41 UR - https://doi.org/10.3892/ijo.2012.1649 DO - 10.3892/ijo.2012.1649 ID - Liu2012 ER - TY - JOUR AU - Afshar-Oromieh, A. AU - Debus, N. AU - Uhrig, M. PY - 2018 DA - 2018// TI - Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer JO - Eur J Nucl Med Mol Imaging VL - 45 UR - https://doi.org/10.1007/s00259-018-4079-z DO - 10.1007/s00259-018-4079-z ID - Afshar-Oromieh2018 ER - TY - JOUR AU - Gupta, P. AU - Murthy, V. AU - Agarwal, A. AU - Maitre, M. AU - Mhatre, N. AU - Rangarajan, V. PY - 2019 DA - 2019// TI - 68Ga-prostate-specific membrane antigen PETCT-based response to androgen deprivation therapy in patients with prostate cancer JO - Nucl Med Commun VL - 40 UR - https://doi.org/10.1097/MNM.0000000000001105 DO - 10.1097/MNM.0000000000001105 ID - Gupta2019 ER - TY - JOUR AU - Sweat, S. D. AU - Pacelli, A. AU - Murphy, G. P. AU - Bostwick, D. G. PY - 1998 DA - 1998// TI - Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases JO - Urology VL - 52 UR - https://doi.org/10.1016/S0090-4295(98)00278-7 DO - 10.1016/S0090-4295(98)00278-7 ID - Sweat1998 ER - TY - JOUR AU - Silver, D. A. AU - Pellicer, I. AU - Fair, W. R. AU - Heston, W. D. AU - Cordon-Cardo, C. PY - 1997 DA - 1997// TI - Prostate-specific membrane antigen expression in normal and malignant human tissues JO - Clin Cancer Res VL - 3 ID - Silver1997 ER - TY - JOUR AU - Lohaus, F. AU - Zöphel, K. AU - Löck, S. PY - 2019 DA - 2019// TI - Can local ablative radiotherapy revert castration-resistant prostate cancer to an earlier stage of disease? JO - Eur Urol VL - 75 UR - https://doi.org/10.1016/j.eururo.2018.11.050 DO - 10.1016/j.eururo.2018.11.050 ID - Lohaus2019 ER - TY - JOUR AU - Emmett, L. AU - Yin, C. AU - Crumbaker, M. PY - 2019 DA - 2019// TI - Rapid modulation of PSMA expression by androgen deprivation: serial 68Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade JO - J Nucl Med VL - 60 UR - https://doi.org/10.2967/jnumed.118.223099 DO - 10.2967/jnumed.118.223099 ID - Emmett2019 ER - TY - JOUR AU - Afshar-Oromieh, A. AU - Holland-Letz, T. AU - Giesel, F. L. PY - 2017 DA - 2017// TI - Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients JO - Eur J Nucl Med Mol Imaging VL - 44 UR - https://doi.org/10.1007/s00259-017-3711-7 DO - 10.1007/s00259-017-3711-7 ID - Afshar-Oromieh2017 ER - TY - JOUR AU - Afshar-Oromieh, A. AU - Avtzi, E. AU - Giesel, F. L. PY - 2015 DA - 2015// TI - The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer JO - Eur J Nucl Med Mol Imaging VL - 42 UR - https://doi.org/10.1007/s00259-014-2949-6 DO - 10.1007/s00259-014-2949-6 ID - Afshar-Oromieh2015 ER -